相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Tu1148 Mechanisms of Loss of Response to Adalimumab in Crohn's Disease
Douglas C. Wolf et al.
GASTROENTEROLOGY (2015)
Tu1169 Correlation Between Adalimumab Trough Serum Concentration, Anti-Adalimumab Antibodies and TNF-α Levels With Clinical Outcome in Patients Affected by Crohn's Disease
Giorgia Bodini et al.
GASTROENTEROLOGY (2015)
Su1219 Accurate Determination of Serum Adalimumab and Anti-Adalimumab Antibodies Levels During Maintenance Therapy for Crohn's Disease
Hirotsugu Imaeda et al.
GASTROENTEROLOGY (2015)
157 Fecal Loss of Infliximab As a Cause of Lack of Response in Severe Inflammatory Bowel Disease
Johannan F Brandse et al.
GASTROENTEROLOGY (2015)
490 Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between Ata and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients
Fernando S. Velayos et al.
GASTROENTEROLOGY (2015)
Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2014)
The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis
Sandra Garces et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNFα biologics in rheumatic diseases
C. C. Mok et al.
CLINICAL RHEUMATOLOGY (2013)
Serum Adalimumab Concentration and Clinical Remission in Patients with Crohn's Disease
Yi-Lin Chiu et al.
INFLAMMATORY BOWEL DISEASES (2013)
Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay
Shui-Long Wang et al.
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS (2013)
Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
C. Reenaers et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
The decline of anti-drug antibody titres after discontinuation of anti-TNFs: implications for predicting re-induction outcome in IBD
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2012)
Therapeutic Drug Monitoring of Tumor Necrosis Factor Antagonists in Inflammatory Bowel Disease
Ingrid Ordas et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Crohn's disease patients treated with adalimumab benefit from co-treatment with immunomodulators
Mirthe E. van der Valk et al.
GUT (2012)
Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment
N. Vande Casteele et al.
GUT (2012)
Clinical utility of antihuman lambda chain-based enzyme-linked immunosorbent assay (ELISA) versus double antigen ELISA for the detection of anti-infliximab antibodies
Uri Kopylov et al.
INFLAMMATORY BOWEL DISEASES (2012)
Loss of Response and Need for Adalimumab Dose Intensification in Crohn's Disease: A Systematic Review
Vincent Billioud et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
The immunogenic part of infliximab is the F(ab ')(2), but measuring antibodies to the intact infliximab molecule is more clinically useful
Shomron Ben-Horin et al.
GUT (2011)
Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up
Geertje M. Bartelds et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
Importance of Neonatal FcR in Regulating the Serum Half-Life of Therapeutic Proteins Containing the Fc Domain of Human IgG1: A Comparative Study of the Affinity of Monoclonal Antibodies and Fc-Fusion Proteins to Human Neonatal FcR
Takuo Suzuki et al.
JOURNAL OF IMMUNOLOGY (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
T. R. D. J. Radstake et al.
ANNALS OF THE RHEUMATIC DISEASES (2009)
Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease
Konstantinos Karmiris et al.
GASTROENTEROLOGY (2009)
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
R. L. West et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2008)
Activation of the JAK/STAT-1 signaling pathway by IFN-γ can down-regulate functional expression of the MHC class I-related neonatal Fc receptor for IgG
Xindong Liu et al.
JOURNAL OF IMMUNOLOGY (2008)
Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
Geertje M. Bartelds et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Adalimumab induction therapy for Crohn disease previously treated with infliximab - A randomized trial
William J. Sandborn et al.
ANNALS OF INTERNAL MEDICINE (2007)
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
Jean-Frederic Colombel et al.
GASTROENTEROLOGY (2007)
Clinically active Crohn's disease in the presence of a low C-reactive protein
THJ Florin et al.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2006)
Antibody pharmacokinetics and pharmacodynamics
ED Lobo et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2004)
分享论文
